MSI 404

Drug Profile

MSI 404

Latest Information Update: 14 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genaera Corporation
  • Class Eye disorder therapies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acanthamoeba infections

Most Recent Events

  • 30 Jul 1998 No-Development-Reported for Acanthamoeba infections in USA (Ophthalmic)
  • 13 Sep 1996 New profile
  • 13 Sep 1996 Preclinical development for Acanthamoeba infections in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top